ЛЕЧЕНИЕ ЭРЕКТИЛЬНОЙ ДИСФУНКЦИИ У ПАЦИЕНТОВ С РАКОМ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ ПОСЛЕ РАДИКАЛЬНОЙ ПРОСТАТЭКТОМИИ

Prostate cancer (PC) treatment is a pressing problem both inRussiaand worldwide. According to data for Saint-Petersburg, from 1990 to 2002 morbidity increase rate for PC was 141.3 %. Even after nerve-sparing radical prostatectomy (RP) erectile dysfunction of some level is observed in 65–75 % of patients. During follow-up examination, data on sexual history were gathered including information on past and current sexual contacts. A questionnaire based on the International Index of Erectile Function was used which allows to evaluate different parameters of sexual function (sexual drive, erection, orgasm, ejaculation, sexual act, and satisfaction with sexual relationships), as well as determine treatment effectiveness. We performed combined two-stage treatment of erectile dysfunction in patients with PC after RP. At the first stage, phosphodiesterase type 5 inhibitors (sildenafil 100 mg) were used. If the drug was ineffective, the second stage was initiated (intracavernosal alprostadil injections). Drug effectiveness, complications, patient compliancy were evaluated.